Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

CV had an increased efficacy compared with E in an unselected population of elderly patients with advanced NSCLC.